Dermatophagoides Pteronyssinus / House Dust Mite
House dust mite extract (Dermatophagoides pteronyssinus) is an allergenic extract used for skin testing to diagnose mite allergy and for immunotherapy (allergy shots) to reduce symptoms in people with a confirmed mite allergy.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
This product can cause severe allergic reactions and death — especially in people with steroid-dependent or unstable asthma. It must only be administered by or under the close supervision of a physician experienced in allergy and allergenic extracts. Your first dose must be based on skin testing results. You must be watched for at least 20 minutes after every injection, and emergency equipment must be on hand. If you are switching from a different type or lot of extract, your dose will be restarted at a much lower level. If you take beta-blocking drugs, tell your doctor — these can interfere with the emergency treatment (epinephrine) used if you have a serious reaction. This product must never be injected into a vein.
📖 Dermatophagoides Pteronyssinus / House Dust Mite: Patient Information Guide
A plain-language walkthrough of Dermatophagoides Pteronyssinus / House Dust Mite — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
House dust mite extract is an allergenic extract with two main uses: confirming a mite allergy through skin testing, and reducing allergy symptoms through immunotherapy (allergy shots).
- Allergy diagnosis: Used via scratch, prick-puncture, or intradermal skin testing to identify sensitivity to house dust mites in patients with a history of mite or house dust allergy
- Allergy immunotherapy (treatment): Used by subcutaneous injection in patients whose mite allergy has been confirmed by skin testing, to help reduce symptoms associated with house dust allergy
- Both uses require physician supervision by someone with specialized allergy training
⚙️How it works▾
For skin testing, the extract works by triggering a local immune response: the mite allergen binds to IgE antibodies (allergy-specific proteins) on the surface of mast cells (immune cells in the skin), causing them to release histamine and other chemicals. This produces the familiar small raised bump (wheal) and redness (erythema) that signals an allergy is present.
For immunotherapy, the exact mechanism is not fully understood, but it is generally believed that gradually introducing increasing amounts of the mite allergen helps train the immune system to be less reactive, reducing allergy symptoms over time.
💊How it's taken▾
Dosing is highly individualized and must be determined by a physician based on skin test results and your sensitivity level.
- Diagnostic skin testing: Applied cutaneously (scratch or prick-puncture) or intradermally — intradermal testing is only done if the scratch/prick test is negative
- Immunotherapy injections: Given subcutaneously (under the skin), typically one to two times per week at the start; intervals are gradually extended to every two, three, then four weeks as the maintenance dose is reached
- If you miss six to eight weeks or more, your dose will need to be reduced — never restart at your previous dose without guidance from your doctor
- A typical course of immunotherapy is three to five years, though this varies by individual
🤒Side effects — in detail▾
Most side effects happen at the injection site or as generalized allergic symptoms shortly after the injection.
- Redness, itching, swelling, or tenderness at the injection site
- Generalized skin flushing or hives (urticaria)
- Runny nose or nasal congestion
- Wheezing
- Swelling of deeper tissues (angioedema)
- Nausea, stomach cramps, or diarrhea (less common)
- Low blood pressure (hypotension)
Severe reactions — including throat swelling (laryngeal edema), anaphylaxis (a life-threatening whole-body allergic reaction), shock, and loss of consciousness — can occur and require immediate emergency treatment. Fatalities have been reported rarely. Always stay in the clinic for at least 20 minutes after each injection.
⚠️Warnings & precautions▾
Severe and potentially fatal allergic reactions can occur — this is the most important risk. All injections must be given in a medical setting with emergency equipment and trained staff immediately available. People with steroid-dependent or unstable asthma are at the highest risk for life-threatening reactions.
- Hold or delay injections if you have severe asthma or nasal symptoms, a fever or infection, or have had heavy mite exposure before your scheduled visit
- When switching to a new lot or type of extract, your dose must be reduced to no more than 25% of your previous dose — potency can vary
- Beta-blocking drugs can reduce the effectiveness of epinephrine if it is needed in an emergency — your doctor must know if you take these
- Concentrated extract must always be diluted before use; undiluted concentrate is extremely potent
- Any local reaction lasting more than 24 hours, or any sign of a systemic (whole-body) reaction, means your next dose must be reduced
🔀What it interacts with▾
There is one key drug interaction you should know about before starting this treatment.
- Beta-blocking drugs (such as metoprolol, atenolol, propranolol — used for heart conditions, high blood pressure, or other conditions): these medications can make epinephrine less effective if it is needed to treat a severe allergic reaction to the extract — this is a clinically important safety concern your doctor must be aware of before you start injections
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Previous severe reaction: Do not receive immunotherapy if you have had anaphylaxis (severe whole-body allergic reaction) following prior skin testing, allergy shots, or natural mite exposure
- Autoimmune disease: May be at risk of worsening symptoms — your doctor must carefully evaluate the benefit-to-risk balance
- Recent heart attack: Immunotherapy may not be tolerable; requires careful medical evaluation before starting
- Children with nephrotic syndrome (a serious kidney condition): should probably not receive immunotherapy due to the risk of worsening the kidney condition
- Bleeding disorders: Injections should not be given if you have a condition that causes abnormal bleeding
- Beta-blocker users: Tell your doctor — these drugs can interfere with emergency epinephrine treatment if a severe reaction occurs
- Children and older adults generally tolerate the injections well, but all dosing must still be individualized
🚑If you take too much▾
If a dose is too large and causes a significant local reaction (swelling, redness, pain at the injection site), it can be treated with oral antihistamines and a cold compress applied to the area — but no further extract should be given until the reaction has completely resolved, and the next dose must be reduced. A severe systemic (whole-body) reaction, such as anaphylaxis, must be treated immediately with epinephrine. Always report any reaction to your doctor before your next scheduled injection.
📡Pharmacodynamics — effects in the body▾
When used for skin testing, house dust mite extract causes a measurable wheal (raised bump) and erythema (redness) response at the test site within 15 to 20 minutes. The size of this response — measured in millimeters — reflects the degree of allergic sensitivity to mite allergens. For immunotherapy, the measurable goal is a reduction in allergy symptoms over the course of treatment, though the precise biological changes underlying this effect are not fully established.
📦How to store it▾
Extract should be stored at 2-8°C since higher temperatures may adversely affect stability. Do not freeze.
📄 Written from Dermatophagoides Pteronyssinus / House Dust Mite’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Dermatophagoides Pteronyssinus / House Dust Mite — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is this shot, and why has my doctor recommended it? ▾
Is it safe? I've heard allergy shots can cause serious reactions. ▾
What side effects should I expect, and when should I call for help? ▾
Do I have to come in that often? How long does treatment take? ▾
I take a blood pressure medication called a beta-blocker. Does that matter? ▾
What happens if I miss a few appointments? ▾
Is Dermatophagoides Pteronyssinus / House Dust Mite available over the counter? ▾
When was Dermatophagoides Pteronyssinus / House Dust Mite first available? ▾
💬 Answers drafted from Dermatophagoides Pteronyssinus / House Dust Mite’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Dermatophagoides Pteronyssinus / House Dust Mite comes
Dermatophagoides Pteronyssinus / House Dust Mite is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Used cutaneously (scratch or prick-puncture) or intradermally to diagnose mite allergy through skin testing
- Used by subcutaneous injection for immunotherapy (allergy shot treatment) in patients with confirmed mite allergy
- Intradermal testing is only performed after a scratch or prick-puncture test has been done with a negative result
- Must never be injected intravenously — subcutaneous and intradermal routes only for treatment and diagnostic testing
- The concentrate must be diluted before use for intradermal skin testing or therapeutic injection; never use undiluted concentrate directly on a patient
- For subcutaneous immunotherapy, injections are typically given one to two times per week initially, with intervals gradually extended to every four weeks at maintenance — follow your prescriber's exact schedule
- Stay at the clinic for at least 20 minutes after every injection so you can be monitored for reactions
📊 Dermatophagoides Pteronyssinus / House Dust Mite across the U.S. market
How Dermatophagoides Pteronyssinus / House Dust Mite appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
🔍 Compare Dermatophagoides Pteronyssinus / House Dust Mite products
A representative set of FDA-listed product records for Dermatophagoides Pteronyssinus / House Dust Mite — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10000 [AU]/mL | Cutaneous, Intradermal, Subcutaneous | Allermed Laboratories, Inc. | BLA | View NDC → |
| 10000 [AU]/mL | Cutaneous; Intradermal; Subcutaneous | Allermed Laboratories, Inc. | BLA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Dermatophagoides Pteronyssinus / House Dust Mite NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dermatophagoides Pteronyssinus / House Dust Mite — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dermatophagoides Pteronyssinus / House Dust Mite in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Dermatophagoides Pteronyssinus / House Dust Mite went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 1116982 2 dose forms · 3 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 1116981In current FDA listingsClinical drug / strength (SCD) American house dust mite allergenic extract 15000 AU/ML / European house dust mite allergenic extract 15000 AU/MLRxCUI 1192764American house dust mite allergenic extract 5000 AU/ML / European house dust mite allergenic extract 5000 AU/MLRxCUI 1192787 -
Dose form (SCDF) Sublingual Tablet RxCUI 1998623No current FDA listingClinical drug / strength (SCD) American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDMRxCUI 1998624
Look up RxCUI 1116982 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Dermatophagoides Pteronyssinus / House Dust Mite is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏭 Manufacturers & labelers
RxNorm drug class
Dermatophagoides Pteronyssinus / House Dust Mite belongs to the Standardized Insect Allergenic Extract class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Allermed Laboratories, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.